Efficacy and Safety of PD-1 Inhibitors Combined with Transarterial Chemoembolization (TACE) and targeted Therapy in Advanced Primary Hepatocellular Carcinoma
Retrospective analysis found improved objective response and progression-free survival in liver cancer patients with triple therapy, suggesting enhanced treatment options.
Key Points
Triple therapy with pd-1 inhibitors, tace, and targeted therapy demonstrated a 56.3% objective response rate compared to 19.4% in the control group.
The study included 68 patients with advanced primary hepatocellular carcinoma from several hospitals in China.
Adverse reactions were mostly mild, with no severe events reported, indicating a favorable safety profile.
This combination strategy offers significant improvements in efficacy, emphasizing potential for better patient outcomes.